摘要
目的研究紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌的不良反应和近期疗效。方法 120例晚期非小细胞肺癌患者,随机分为试验组(A组)和对照组(B组),A组采用紫杉醇脂质体135mg/m2,顺铂60～80mg/m2,B组采用紫杉醇135mg/m2化疗,顺铂剂量同A组,21天为1周期。2周期评价疗效及化疗期间的不良反应,并观察各组近期疗效。结果 A组的周围神经炎、呼吸困难、面色潮红、肌肉痛、皮疹、心律失常、低血压、痤疮、毛囊炎、口腔溃疡的发生率明显低于B组(P<0.05)。两组的恶心、呕吐、骨髓抑制、腹泻、便秘、肝肾功能损伤、心功能、血脂、脱发、脉管炎、液体潴留等方面发生率差异无统计学意义。两组组有效率(RR)为41.6%(25/60)和35.6%(21/59),临床受益率(DCR)为78.3%(47/60)和69.5%(41/59),经比较差异无均无统计学意义(P>0.05)。结论紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌疗效确切,不良反应比紫杉醇联合顺铂化疗轻微。
Objective To evaluate the short-term efficacy and the toxic reaction of paclitaxel liposome plus cisplation（DDP） in non-small sell lung cancer（NSCLC） patients. Methods 120 advanced-stage NSCLC patients were randomized into experiment group（group A） and control group（group B） ,the patients in group A were given paclitaxel liposome 135 mg/m2 plus DI）P 25 mg/m2 ,and those in group B were given paclitaxel 135 mg/m2 plus DIDP 25 mg/m2. One cycle lasted for 21 days. Both groups received these regiments for two cycles,then the short-term efficacy and the toxic reaction were evaluated. Results The incidence of peripheral neuritis, difficulty breathing, facial flushing, muscle pain, skin rash,arrhythmia,low blood pressure,acne,hair follicle inflammation,oral ulcer of group A were significantly lower than those of group B（ P ~ 0.05）. The incidence of nausea, vomiting, bone marrow inhibition, diarrhea, constipation,liver and kidney damage, heart function, blood fat and hair loss, vasculitis, fluid retention of the two groups showed no statistical significance. The overall response rates were 41.6% （25/60） vs 35.6% （21/59）, and the disease control rates were 78.3%（47/60） vs 69.5%（41/59） in group A and group B（both P ~0.05）. Conclusion Paclitaxel liposome combined with DDP is an effective treatment regimen with lower incidence of side effects, compared with trational paclitaxel plus DDP.
出处
《临床荟萃》
CAS
2012年第23期2039-2043,共5页
Clinical Focus
关键词
癌
非小细胞肺
紫杉烷类
脂质体
顺铂
药物毒性
治疗结果
carcinoma, non-small-cell lung
taxoids
liposome
cisplatin
drug toxicity
treatment outcome
